Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | PTPN7 | P35236 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 1/20 | 1.00 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8477662 | 1.00 | HSD17B10 (1.00) | HSD17B10KDM4ETDP1POLBUSP2 | |
| SCHEMBL8477667 | 1.00 | HSD17B10 (1.00) | HSD17B10KDM4ETDP1POLBUSP2 | |
| SCHEMBL30923529 | 0.88 | HSD17B10 (0.79) | HSD17B10KDM4ETDP1POLBUSP2 | |
| SCHEMBL11021033 | 0.88 | HSD17B10 (0.79) | HSD17B10KDM4ETDP1POLBUSP2 | |
| SCHEMBL11021035 | 0.88 | HSD17B10 (0.79) | HSD17B10KDM4ETDP1POLBUSP2 | |
| SCHEMBL10897219 | 0.88 | HSD17B10 (0.79) | HSD17B10KDM4ETDP1POLBUSP2 | |
| SCHEMBL30923527 | 0.88 | HSD17B10 (0.79) | HSD17B10KDM4ETDP1POLBUSP2 | |
| SCHEMBL30923534 | 0.88 | HSD17B10 (0.79) | HSD17B10KDM4ETDP1POLBUSP2 | |
| SCHEMBL9726349 | 0.85 | HSD17B10 (0.73) | HSD17B10KDM4ETDP1POLBUSP2 | |
| SCHEMBL9206274 | 0.85 | HSD17B10 (0.73) | HSD17B10KDM4ETDP1POLBUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | claimed |
| EP-0826678-A1 | Process for preparing optically active benzothiazepine compound, and intermediate therefor | TANABE SEIYAKU CO., LTD. (JP) | 1998-03-04 | — | — | EP | claimed |
| US-5310904-A | Intermediate | TANABE SEIYAKU CO., LTD. (JP) | 1994-05-10 | — | — | US | claimed |
| EP-0551076-A1 | Process for preparing optically active benzothiazepine compounds by asymmetric reduction | TANABE SEIYAKU CO., LTD. (JP) | 1993-07-14 | — | — | EP | claimed |
| JP-8000277-A | — | — | None | — | — | JP | disclosed |
| JP-5244992-A | — | — | None | — | — | JP | disclosed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2012-04-19 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | disclosed |
| US-5945533-A | Process for preparing optically active benzothiazepine compound and intermediate therefor | TANABE SEIYAKU CO., LTD. (JP) | 1999-08-31 | — | — | US | disclosed |
| US-5945533-A | Process for preparing optically active benzothiazepine compound and intermediate therefor | TANABE SEIYAKU CO., LTD. (JP) | 1999-08-31 | — | — | US | disclosed |
| EP-0826678-A1 | Process for preparing optically active benzothiazepine compound, and intermediate therefor | TANABE SEIYAKU CO., LTD. (JP) | 1998-03-04 | — | — | EP | disclosed |
| EP-0826678-A1 | Process for preparing optically active benzothiazepine compound, and intermediate therefor | TANABE SEIYAKU CO., LTD. (JP) | 1998-03-04 | — | — | EP | disclosed |
| CN-1174837-A | Process for preparing optically active benzothiazepine compound, and intermediate therefor | TANABE SEIYAKU CO (JP) | 1998-03-04 | — | — | CN | disclosed |
| JP-H08277-A | PRODUCTION OF OPTICALLY ACTIVE BENZOTHIAZEPIN COMPOUND BY ENZYMATIC REACTION | TANABE SEIYAKU CO LTD | 1996-01-09 | — | — | JP | disclosed |
| US-5310904-A | Intermediate | TANABE SEIYAKU CO., LTD. (JP) | 1994-05-10 | — | — | US | disclosed |
| JP-H05244992-A | PRODUCTION OF OPTICALLY ACTIVE BENZOTHIAZEPINES BY ENZYMIC REACTION | TANABE SEIYAKU CO LTD | 1993-09-24 | — | — | JP | disclosed |
| EP-0551076-A1 | Process for preparing optically active benzothiazepine compounds by asymmetric reduction | TANABE SEIYAKU CO., LTD. (JP) | 1993-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | MCL1, AS3MT, MYADM | HSD17B10 1707/4885KDM4E 3465/4885TDP1 1293/4885 |
| US-20120095032-A1 | METHODS FOR TREATING LEUKEMIA AND MYELODYSPLASTIC SYNDROME, AND METHODS FOR IDENTIFYING AGENTS FOR TREATING SAME | MCL1, AS3MT, MYADM | HSD17B10 1707/4885KDM4E 3465/4885TDP1 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.